The European Myeloma Network

A non-profit organisation created to increase understanding of multiple myeloma and to produce effective research projects and clinical trials.

Read more


Measurable residual disease (MRD)

The most widely used tests are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests use samples of bone marrow cells (taken by aspiration) and/or peripheral blood cells (taken through a vein).

Read more

Clinical trials

EMN Biobanking view

EMN30 view

EMN28 view


View all

About the HARMONY Alliance

Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Various groups participate in HARMONY, including EMN. HARMONY Research Project Leads and Key Opinion Leaders in Multiple Myeloma are Prof. Pieter Sonneveld, Prof. Mario Boccadoro, and Prof. Jesus San-Miguel.

Read more

About EMN

Multiple Myeloma

Multiple myeloma is a rare and highly heterogeneous hematologic
malignancy, and the clinical research certainly plays a fundamental role in
the management of patients with this disease.


To deal with such a complex scenario, in 2005, a group of European
hematologists pulled together to increase their understanding of multiple
myeloma and to produce effective research projects and clinical trials.
These efforts resulted in the creation of the European Myeloma Network
(EMN), a non profit organization.

Read more


Various reviews, guidelines and recommendation papers are produced under the EMN umbrella. To collect & better coordinate the various proposals and manuscripts, a guideline team is in place: Monika Engelhardt from Germany, Niels van de Donk from the Netherlands, Francesca Gay from Italy and Evangelos Terpos from Greece.

Read more

Hear from the EMN President

Diversity and inclusion

Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexualorientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.

Pieter Sonneveld


Mario Boccadoro


Fredrik Schjesvold


Gordon Cook


Heinz Ludwig


Hermann Einsele


Jesus San-Miguel


Meletios Dimopoulos


Philippe Moreau


Roman Hajek


Annemiek Broijl

President - Junior

Cyrille Touzeau


Enrique Ocio


Francesca Gay


Guldane Cengiz Seval


Jakub Radocha


Leo Rasche


Maria Gavriatopoulou


Maria Krauth


Rakesh Popat


Tobias Slordahl



22 April 2023

Thank you – EMN2023 meeting read

05 August 2022

2022 Waldenström Lifetime Achievement Award read


05 May 2023

5th EMN meeting 18-20 April 2024 view

26 October 2022

15th EMN Trialist Forum 5-6 November 2023 – save the date! view


For more information about our trials or events, you can contact us through:

Although we do understand sometimes it is hard to navigate the complex world of multiple myeloma, we cannot provide clinical assessments or consultations by email. Please refer to your treating physicians for any doubts, they certainly have a more complete overview of your medical history and treatments to appropriately assist you.

630-6308222_image-transparent-twitter-icon-png-png-download ... @EMN_EuMMnet

linkedin-icon | Athens GA | W&A Engineering